Additionally, the prothrombotic state of malignant tumors is also driven by cancer-specific pathways, including tumor-related leukocytosis and release of tissue factor, podoplanin, as well as plasminogen activator inhibitor 1 (13). This evidence concerns the gene PDPN and neoplasm.